[ADDRESS_458319] Cancer (PALINA study)  
  
Principal Investigator:   
[INVESTIGATOR_366675], MD  
Assistant Professor of Medicine  
Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospi[INVESTIGATOR_366676]:   
Ming Tan, PhD  
  
Sub-Investigators:  
Georgetown MedStar Cancer Network:   
Claudine Isaacs, MD  
Paula Pohlmann, MD PhD  
Christopher Gallagher, MD  
Robert Warren, MD  
Asma Dilawari, MD  
Mahsa Mohebtash, MD  
Lois Kamugisha, MD  
  
University of Chicago  
Olwen Hahn, MD  
  
Thomas Jefferson University  
Maysa Abu -Khalaf, MD  
  
  
Basic science investigators:  
Ayesha Shajahan -Haq, PhD  
Robert Clarke, PhD  
  
Study Drugs:  Palbociclib  
  
Funding Source:  [COMPANY_007]  
  
Initial version: 1/04/[ADDRESS_458320] Cancer  
  
Protocol No.:        Version date:                                                                                                 
  
  
The signature [CONTACT_32642], and provides  
the necessary assurances that this trial will be conducted according to all stipulations of the  
protocol, including all statements regarding confidentiality, and according to local legal and  
regulatory requirements and applicable U.S. federal regulations and International Conference  
on Harmonization (ICH) guidelines.  
  
  
  
Principal Investigator ( PI) Name :________________________________________________  
  
PI [INVESTIGATOR_7496]: ________________________________________________________________   
  
Date:  _______________________________________________________________________   
  
Name [CONTACT_216906]: ________________________________________________________________  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
  
  
  
 
  
 
  
 
 
3 
 TABLE OF CONTENTS   
  
  
  
STUDY SUMMARY....................................................................................................... ............................. 7  
  
1. INTRODUCTION ..................................................................................................... ..............................10   
  
  1.1. Background ............................................................................................... ............................. 10 
  
1.2. Palbociclib ………… ………………………………………………………………………………. 10 
 
    1.2.1. Preclinical Data........................................................................ ..............................10  
    
1.2.2. Clinical activity ………………………………………………………………………….. 11 
  
   1.2.3. Toxicity ……………............................................................ .................................... .12  
  
  1.3. Minorities enrollment in clinical t rials………………………………….…………………………. 13  
  
  1.4. Neutrophil count in African A mericans………………………………………….………………...1 3  
  
  1.5. Metabolomics and exosomes in endocrine  resistance ……… ……………………………… ….14  
  
  1.6. Study Rationale ........................................................................................................ ............. .14  
  
2. STUDY OBJECTIVES AND ENDPOINTS ........................................................................................... ..15  
  
  2.1. Objectives ............................................................................................................. ................1 5  
  
  2.2. E ndpoints..................................................................................................................... .......... .16  
  
3. STUDY DESIGN................................................................................................... ................................. .16  
  
4. PATIENT SELECTION ........................................................................................................ ..................1 8  
  
  4.1. Inclusion Criteria ....................................................................................................................1 8  
  
  4.2. Exclusion Criteria...................................................................................................... ..............19  
  
5. STUDY TREATMENTS.......................................................................................... ............................... .19  
  
  5.1. Allocation to Treatment ................................................................. .......... .............................. .20  
  
  5.2. Compliance.............................................................................................. .............................. .20 
  
  5.3. Drug Supplies ........................................................................................................................2 0  
  
    5.3.1. Dosage Form(s) and Packaging .............................................. ..............................20   
  
      [IP_ADDRESS]. Palbociclib ................................................................ ..............................20   
 
      [IP_ADDRESS]. Letrozole................................................................... ..............................[ADDRESS_458321] rant…………………………………………………………………... 20  
    
   [IP_ADDRESS]. Anastrozole…………………………………………………………………..20  
    
   [IP_ADDRESS] Exemestane…………………………………………………………………..20  
4 
   
    5.3.2. Preparation and Dispensing  – Palbociclib …………………………………………… 21 
  
    5.3.3. Administrati on........................................................................... ..............................21  
  
      [IP_ADDRESS]. Palbociclib ................................................................. ..............................21  
  
      [IP_ADDRESS]. Letrozole................................................................... ..............................22   
  
      [IP_ADDRESS] . Fulvestr ant…………………………………………………………………..  22  
 
   [IP_ADDRESS]. Anastro zole………………………………………………………………….. 22 
 
   [IP_ADDRESS]. Exeme stane……………………… …………………………………………. 22  
  
    5.3.4. Recommended Dose Modification ........................................... ..............................22   
     
      [IP_ADDRESS]. Dosing Interruptions/Dela ys - Palbociclib……………………………….. .23  
  
      [IP_ADDRESS]. Retreatment Criter ia – Palbociclib ............................ ..............................23  
  
      [IP_ADDRESS]. Dose Reductions - Palbociclib ................................. ..............................24   
  
  5.4. Drug Storage ........................................... ................................................. ..............................25   
  
  5.5. Drug Accountability ................................................................................... ..............................26  
 
  5.6. Concomitant Medication(s) ………………………………………………………………………... 26  
  
    5.6.1. Prohibited Medications ............................................................. ..............................27  
  
    5.6.2. Medications Not Recommended....................................... ..................................... .27  
  
6. STUDY PROCEDURES ……………………………………………………………………………………… .28  
  
6.1. Schedule of events ..................................................................................................... ........... 28  
   
  6.2. Patient Withdrawal ..................................................................................................................3 0  
 
7. ASSESSMENTS....................................................................................................... ..............................31   
  
  7.1. Safety Assessments ................................................................................. ..............................31  
 
    7.1.1. Physical Examination .................................................. ............. ..............................31   
  
    7.1.2. Laboratory Safety Assessments ............................................... ..............................31  
  
  7.2. Tumor Assessments...............................................................................................................3 2  
  
8. ADVERSE EVENT REPORTING................................................................................................... ........32  
  
  8.1. Adverse Events.......................................................................................................... ............3 2  
  
  8.2. Reporting Period ............................................................................ ........................................3 3  
  
  8.3. Definition of an Adverse Event.......................................................................................... .....33  
  
    8.3.1. Medication Errors ………………………………………………………………………..[ADDRESS_458322] Findings .........................................................................................................3 4  
  
  8.5. Serious Adverse Events................................................................................................. ........3 5  
  
    8.5.1. Protocol -Specified Serious Adverse Events ...........................................................3 5  
  
  8.6. Hospi[INVESTIGATOR_059] ........................................................................................ ............................... 35  
   
  8.7. Severity Assessment..................................................................................................... .........3 6  
 
  8.8. Causality Assessment ............................................................................................................3 6  
  
8.9. Withdrawal Due to Adverse  Events………………………………………………………………. 37 
  
  8.10. Eliciting Adverse Event Information ............................... ...................................................... 37  
  
  8.11. Reporting Requirements........................................................................................ ............... 37  
  
    8.11.1. Serious Adverse Event Reporting Requirements ................................................. 37 
  
    8.11.2. Non -Serious Adverse Event Reporting Requirements .......................................... 39  
  
    8.11.3. Sponsor Reporting Requirements to Regulatory Authorities ........................... .....39 
  
9. CORRELATIVE STUDIES……… …………………………………………………………………………….. 39  
  
10. DATA ANALYSIS/STATISTICAL METHODS ......................................................................................[ADDRESS_458323] KEEPI[INVESTIGATOR_1645] ......................................................................................4 4  
  
  12.1. Case Report Forms/Electronic Data Record ........................................................................ [ADDRESS_458324]  (IRB)………………………………………………………………… .[ADDRESS_458325] of the Study ……………………………………………………………………. ..45 
  
  13.3. Patient Information and 
Consent .......................................................................................... .45 
  
  13.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ................... .46  
  
  13.5 Amendments to the  protocol………………………………………………… ……………………. [ADDRESS_458326] OF TABLES   
  
Table 1. Study summary ............................................................................................... ...............................7   
  
Table 2. Available Dose Levels .............................................................................................. ...................2 4  
  
Table 3. Palbociclib Dose Modifications for Treatment Related Hematologic Toxicities ...........................2 5  
  
Table 4. Palbociclib Dose Modifications for Treatment Related non -Hematologic Toxicities ....................2 5  
  
Table 5. Schedule of Events …................................................................................... ...............................[ADDRESS_458327] OF FIGURES  
  
Figure 1. Study design………………… …………………………………………… …………………………… 16  
  
  
  
APPENDICES   
  
Appendix 1. Eastern Cooperative Oncology Group (ECOG) Performance Status ....................................[ADDRESS_458328] of Abbreviation .................................................................................. ..............................51   
  
Appendix 3. Patient Medication Dia ry…………………………………………………………………………... [ADDRESS_458329] cancer  
Protocol Number  2015 -1396  
Phase  Phase II study  
Study Duration  24 months; enrollment over 12 months   
 
Study Center(s)  The study will open at the Georgetown MedStar Cancer Network, 
University of Chicago and Thomas Jefferson University  
 
 
 
 
Primary Objective  To evaluate the hematological safety of palbociclib with letrozole or 
fulvestrant in African American women with hormone receptor positive 
HER2 negative advanced breast cancer. Use of anastrozole or 
exemestane permitted in the event of letrozole intoleranc e.  
Hematological safety is a composite endpoint of epi[INVESTIGATOR_366677]   
• To evaluate delays in palbociclib therapy attributed to neutropenia  
• To evaluate dose reductions in palbociclib therapy attributed to       
 neutropenia  
• To evaluate grade 3/4 neutropenia  
• To evaluate the efficacy of palbociclib with letrozole or f ulvestrant in  
 African American women with ER/PR positive HER2 negative     
 metastatic breast cancer with evaluable disease. Use of anastrozole  
 or exemestane permitted in the event of letrozole intolerance.          
• To evaluate correlations between pr oliferation rates and efficacy  
• To describe baseline absolute neutrophil count (ANC) prior to cancer  
 diagnosis and the Duffy Null polymorphism (SNP rs2814778 at  
 chromosome 1q23.2) and explore correlations with hematological   
 safety  
  
8 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Important inclusion 
and exclusion 
criteria  Main inclusion criteria:  
 
1. Self -identified Black, African or African American women of ≥ [ADDRESS_458330] (locoregionally recurrent or metas tatic disease)  
 
2. ER -positive and/or PgR -positive tumor based on local laboratory 
results  
 
3. HER2 -negative breast cancer based on local laboratory results (test 
to be used as per local practice)  
 
4. Patients must be appropriate candidates for letrozol e or fulvestrant 
therapy .  Use of anastrozole or exemestane permitted in the event of 
letrozole intolerance.   
 
5. Eastern Cooperative Oncology Group (ECOG) performance status 
0-2   
 
6. Adequate bone marrow function:  
 
- Absolute Neutrophil Count (ANC) ≥ 1,000/mm 3 (1.0 x 10 9/L);  
- Platelets ≥100,000/mm 3 (100 x 10 9/L);  
- Hemoglobin ≥9 g/dL (90 g/L).  
  
Main exclusion criteria:  
 
1. Current use of food or drugs known to be potent inhibitors or 
inducers of CYP3A4  
 
2. Active uncontrolled or symptomatic brai n metastases. Previously 
treated and clinically stable, as per Investigator’s judgment, brain 
metastases are permitted.  
 
3. Previous CDK4/6 inhibitor  
 
 
Primary endpoint   
Proportion of patients who complete planned oncologic therapy without 
the development of a hematological event defined as epi[INVESTIGATOR_366678] o f neutropenia  
  
9 
  
 
 
 
 
 
 
Secondary endpoint   
• Number of patients who required dose delays in palbociclib attributed  
 to neutropenia.          
• Number of patients who required dose reductions in palbociclib  
 therapy attributed to neutropenia  
• Rate of grade 3/4 neutropenia  
• Clinical benefit rate (for those with evaluable disease) at 24 weeks  
• To evaluate correlations between metabolite and exosomal signature  
 [CONTACT_366725]  
• To evaluate correlations between baseline ANC prior to cancer  
 diagnosis and the Duffy Null polymorphism (SNP rs2814778 at  
 chromosome 1q23.2) with hematological safety  
 
 
Correlative studies    
 
Metabolite biomarkers and exosomal signature [CONTACT_366726], Doses, 
Routes, Regimens  Palbociclib 125mg once daily taken with food for 21 days followed by 7 
days off treatment. For patients enrolled with baseline ANC bet ween 
1000 and 1499/uL, initial dose of palbociclib will be 100mg once daily 
for 21days followed by 7 days off treatment.  
Duration of drug 
administration   Maximum of 12 months.   
 
 
 
 
 
 
 
Statistical 
Methodology  The study is designed to assess the rate of completion of planned 
oncology therapy in the absence of a hematological event defined as 
epi[INVESTIGATOR_366679]. A completion rate of 80% is considered o f clinical 
relevance as to benefit breast cancer patients who are at a higher risk 
of having ethnic neutropenia where as a completion rate of 60% is 
considered poor and to justify additional safety studies. A two stage 
design with a total of [ADDRESS_458331] 80% versus if it is below 60% with 80% power at a significance 
level of 5%.   
 
An exact confidence interval of the completion rate will be calculated. 
We estimate there will be no more than a 10% rate of feb rile 
neutropenia. Due to the small sample size, the analysis of secondary 
endpoints will be descriptive and will not include specific hypothesis 
testing.   
 
  
 
 
 
 
 
10 
 1. INTRODUCTION  
  
1.1. Background  
  
Hormone receptor (HR) positive human epi[INVESTIGATOR_3506] 2 (HER2) 
negative breast cancer is the most common subset of breast cancer. [ADDRESS_458332] cancer, particularly  for those with slowly progressive disease 
and limited tumor -related symptoms. 3 Studies of estrogen receptor (ER) positive breast cancer 
cell lines indicate that estrogens [ADDRESS_458333] on sensitive populations of cells in 
early to mid -G1 phase. G1/S transition is under the control of cyclin -dependent kinases (CDKs) 
activated by [CONTACT_4638].  
 
Conversion of androgens to estrogens via aromatase enzyme action represents the main 
source of estrogens in post -meno pausal women. Letrozole is an oral nonsteroidal aromatase 
inhibitor that is approved worldwide for the first line treatment of post -menopausal women with 
HR positive advanced breast cancer. Letrozole is administered orally in a continuous regimen at 
a 2.[ADDRESS_458334] cancer, letrozole was superior to tamoxifen for time to progression (TTP), time 
to treatment failure (TTF), overall response rate (ORR), and overall clinical benefit response 
(CBR). [ADDRESS_458335] cancer. The 
compound inhibits cell proliferation by [CONTACT_366705] G1 into the 
S phase. In February 3, 2015 the FDA granted accelerated approval to palbociclib (IBRANCE®) 
in combination with letrozole for first -line therapy of postmenopausal women with locally 
advanced or metastatic ER -positive HER2 -negative breast cancer.  
  
1.2.1. Preclinical Data   
 
Palbociclib inhibits purified CDK4 -catalyzed phosphorylation of retinoblas toma protein with an 
IC50 of less than 20 nM, and also tumor growth of several types of human xenograft tumors 
(SF-295, MDA -MB-435, Colo -205, and others) grown in mice. Treatment of cultured tumor cells 
with palbociclib causes growth arrest that is accompa nied by [CONTACT_366706] (Rb) phosphorylation by [CONTACT_140965]4 or CDK6 on residues serine -780 and -795 of Rb.    
 
 
11 
 Palbociclib was tested in vitro on molecularly characterized human BC cell lines. Results from 
these experiments indicate th at those cell lines that are more sensitive to palbociclib (IC50 <150 
nM) have low levels of CDKN2A (p16) and high levels of Rb1, while resistant cell lines show the 
opposite characteristics. Sensitive cell lines in this panel represent mostly the luminal ER 
positive subtype. [ADDRESS_458336] treatment received palbociclib 
once daily for 14 days followed by 7 d ays off (2 weeks on/1 week off). 8 Overall it was well 
tolerated with dose -limiting toxicities (DLTs) related primarily to myelosuppresion. There was 1 
partial response (PR) and 9 patients had stable disease (SD). The recommended phase II dose 
(RP2D) was [ADDRESS_458337] cancer. In this trial, palbociclib was administered 
on a different dose schedule, with 21 days on followed by 7 days off (3 weeks on/1 week off). 
Neutropenia was the only dose -limiting effect and the most common nonhematologic grade 3/4 
adverse events (AEs) included fatigue, nausea, and abdominal pain. Of the [ADDRESS_458338] cancer. 10 Thirty -seven patients were 
enrolled and 19 % had a CBR, defined as PR and SD for 24 months or longer. Median 
progression -free-survival (PFS) was 3.7 months overall but was significantly longer for those 
with HR positive disease compared with HR negative disease (4.5 vs 1.5 months, P = .03).   
 
Base d on preclinical data demonstrating synergy of palbocliclib with anti -estrogen therapy 7, Finn 
et al conducted the PALOMA -1 trial. 11 This multicenter, open -label phase II trial enrolled 165 
postmenopausal women with ER positive HER2 negative, advanced breas t cancer who had not 
received previous systemic treatment for advanced disease. Patients were randomized in a 1:1 
fashion to letrozole 2.5mg daily or letrozole 2.5mg daily plus palbociclib. Median investigator -
assessed PFS was 20.2 months (95% CI 13.8 -27.5) in the palbociclib plus letrozole arm and 
10.2 months (95% CI 5.7 -12.6) in the letrozole alone arm (hazard ratio [HR], 0.488, 95% CI 
0.319 -0.748). In addition, the ORR in patients with measurable disease was higher in the 
palbociclib plus letrozole compa red with the letrozole alone arm (55.4% vs 39.4%).   
 
 
While the results of the phase II study PALOMA -[ADDRESS_458339] cancer: PALOMA -2.[ADDRESS_458340] 
cancer, prior CDK 4/6 inhibitors, nor prior (neo)adjuvant treatment with letrozole or anast rozole 
with a disease free interval less than 12 -months from completion of treatment. Patients were 
assigned to letrozole with palbociclib 125 mg once daily 3 weeks on/1 week off or to letrozole  
with placebo. This study has completed accrual and results a re expected in 2016.   
 
Palbociclib has also been investigated in the second -line setting. In PALOMA -3 study, a phase 
III randomized (2:1) double blind study, [ADDRESS_458341] 
cancer that relapsed or progressed on previou s endocrine therapy were assigned to fulvestrant 
with palbociclib or placebo. 13 Premenopausal or perimenopausal women were eligible if also 
treated with goserelin. Women on the experimental arm had more than double median PFS 
(primary endpoint) compared wi th those in the placebo arm (9.2 months vs 3.8 months, HR 
0.42, P <.001). The relative difference in primary outcome between the placebo and palbociclib 
groups was consistent regardless of menopausal status of the patients. At the time of this 
preplanned i nterim analysis, data on overall survival (secondary endpoint) were immature. 
Although the efficacy benefit was not as large as seen in the first -line setting, these results have 
led to an expansion of the currently approved label of palbociclib in breast cancer. In February 
2016 the FDA approved the use of palbociclib in combination with fulvestrant in women with 
HR+ HER2 - advanced or metastatic breast cancer after progression on endocrine therapy.   
  
1.2.3. Toxicity  
 
Palbociclib is overall well tolerate d, either as monotherapy or in combination with anti -estrogen 
therapi[INVESTIGATOR_014]. However quite often dosage reductions or treatment delays are required primarily due 
to hematologic toxicity. In the phase I study reported by [CONTACT_366707], 9 neutropenia was the 
dose -limiting toxicity and there was a relatively small incidence of grade 3 neutropenia (12%) 
and anemia (7%). Surprisingly in the single arm phase II study where palbociclib was also given 
as monotherapy, neutropenia was significantl y higher and grade 3/4 neutropenia, anemia, and 
thrombocytopenia were reported in 51%, 5%, and 22% of patients, respectively. Of note, 24% of 
patients had treatment interruption and 51% had dose reductions, all due to cytopenias. [ADDRESS_458342] common grade 3/4 toxicities were also hematologic. What 
seemed to be unexpected was the finding that although grade 3/4 neutropenia was reported in 
54% of patients in the experimental arm, no cases of febrile neutropenia or neutropenia -related 
infections were seen. Among the nonhematologic all -grade AEs, the most common were fatigue 
(40%), nausea (25%), arthralgia (23%), and diarrhea (21%). Importantly, 43% of patients 
enrolled had received previous chemotherapy in the neoadjuvant or adjuvant se tting.  
 
In the PALOMA -[ADDRESS_458343] 
common adverse event occurring in 78.8% of patients receiving palbociclib -fulvestrant (any 
grade). Grade 3/4 neutropenia occurred in 62% of patients in the  palbociclib arm compared with 
0.6% in the placebo arm. In this study, low rates of neutropenia -related complications and  
 
 
febrile neutropenia were also confirmed and were reported in 0.6% of patients in each arm. 
13 
 Remarkably, 31.6% of patients required d osage reduction of palbociclib.   
  
1.3. Minorities enrollment in clinical trials  
 
The National Institute of Health (NIH) guidelines on the inclusion of women and minorities in 
clinical trials published in [ADDRESS_458344]. According to a 2011 report from the conference "Dialogues on 
Diver sifying Clinical Trials," sponsored by [CONTACT_1622], African Americans represent 12% of the 
U.S. population but only 5% of clinical trial participants and Hispanics make up 16% of the 
population but only 1% of clinical trial participants.  
  
1.4. Neutrophil count in  African Americans   
 
Benign ethnic neutropenia (BEN) is a condition used to describe individuals with neutrophil 
counts less than 1.5x10 9cells/L in the absence of other causes. 16 It is common in people of 
African ancestry, including African Americans, and  identifies a group (estimated in 50% of 
African Americans) with low absolute neutrophil count (ANC) but no increased risk of 
agranulocytosis or infection. Published evidence implicates a polymorphism (SNP rs2814778 at 
chromosome 1q23.2) in the Duffy Antig en Receptor Chemokine (DARC) gene in the 
pathophysiology of BEN. 17   
 
An ANC cutoff at 1.5x10 9 cells/L for trial enrollment for African American patients when many 
have ethnic neutropenia may not be necessary. 18 Currently there are insufficient data to indicate 
that individuals with BEN would face a higher risk of febrile neutropenia greater than those 
without BEN. In a recent pi[INVESTIGATOR_366680] a group of investigators from the University of 
Maryland (not publis hed yet), 12 African American patients with BEN and schizophrenia 
received clozapi[INVESTIGATOR_050] (associated with neutropenia) safely and successfully continued despi[INVESTIGATOR_366681]. In addition it has been reported that African 
Amer ican women with early breast cancer have lower white blood count (WBC) after 
chemotherapy and longer duration of treatment resulting in lower dose intensity of treatment 
which can contribute to observed racial differences in breast cancer survival. In this  
retrospective study there was no mention to an increased risk of febrile neutropenia in African 
American women compared to white. [ADDRESS_458345] been underrepresented in clinical trials with palbociclib. This 
may be partially explained b y rigid requirements for minimal WBC numbers (absolute neutrophil 
14 
 count of 1500/mm 3 or higher). In the clinical trials where palbociclib was used for treatment of 
advanced breast cancer and have been published thus far, in PALOMA -1 there is no 
demographics  available for the race/ethnicity of the participants, and in PALOMA -3 there is 
mention that 5.8% of patients enrolled in the experimental arm self -identified as black or other. 
Therefore conclusions regarding the rate of neutropenia and febrile neutropeni a in African 
American patients treated with palbociclib cannot be safely extrapolated from the trials 
previously discussed.   
  
1.5. Metabolite and exosomal signature [CONTACT_366727] a novel “omics” tool with promising clinical applications including breast 
cancer 20. Onco -metabolites identified in blood, tissue or urine can be used as biomarkers of 
cancer 21,22. While the metabolite signature [CONTACT_366728], we have identified an increa sed dependence on glutamine metabolism in endocrine 
resistant breast cancer cell models 23. Metabolic profile of serially collected blood samples have 
enabled detection of breast cancer relapse 24. In this correlative study, untargeted metabolomics 
analysis of serum will allow identification of metabolite markers of endocrine resistance by 
[CONTACT_366708] -responders. Furthermore, clinical data 
such as diabetes, body mass index (BMI) or cardiovascular history will be h elpful in stratifying 
our findings.     
  
In breast cancer, exosomes (30 -120 nm structures that are derived from cell membranes) have 
been suggested as a means of cell -to-cell communication that can be deregulated 25. Exosomes 
are present in most human body  fluids, including blood plasma/serum, saliva, breast milk, 
cerebrospi[INVESTIGATOR_872], urine and semen). These vesicles contain multiple proteins, DNA, mRNA, 
miRNA, long non -coding RNA, and even genetic materials of viruses or prions 26. 
Characterization of exoso mes can be useful as predictive biomarker signatures of drug 
resistance in the clinic 27,28. Preliminary studies in our laboratory show distinct contents in 
exosomes derived from endocrine sensitive versus resistant cells.   
  
1.6. Study Rationale   
 
The proposal  of this study is to evaluate the hematological safety of palbociclib in combination 
with letrozole or fulvestrant in African American women with hormone receptor positive HER2 
negative advanced breast cancer. Currently there are insufficient data to descr ibe the 
hematological safety for these individuals who have a high incidence of BEN.  
 
We propose to lower the ANC cutoff for the enrollment of African American patients to 
1000/mm [ADDRESS_458346] lower limit of ANC of 1500/mm [ADDRESS_458347] cancer. Use 
of anastrozole or exemestane permitted in the event of letrozole intoleranc e.  
 
Hematological safety is defined as a composite endpoint of epi[INVESTIGATOR_366682].  
  
 Secondary Objectives  
  
1. To evaluate delays in palbociclib therapy attributed to neutropenia  
2. To evaluate dose reductions in palbociclib therapy attributed to neutropenia  
3. To evaluate grade 3/[ADDRESS_458348] cancer with evaluable disease .  Use of 
anastrozole or exemestane permitted in the event of letrozole intolerance.   
5. To describe metabolite and exosomal signature [CONTACT_366729] e correlations with disease 
response  
6. To describe baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP 
rs2814778 at chromosome 1q23.2) and explore correlations with hematological safety   
   
2.2. Endpoints   
  
Primary Endpoint  
  
Proportion of patients who complete planned oncologic therapy without the development of a 
hematological event defined as epi[INVESTIGATOR_366683].  
 
If a patient comes off study prior to cycle 1 day 14, that patient will be replaced.  
  
There are different definitions of febrile neutropenia but for study purpose this will be defined 
according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0: “ANC less than 1000/mm 3 with a single temperature of >38.3 degrees 
Celsius (101 degrees Fahrenheit) or a sustained temperature of 38 degrees Celsius (100.4 
degrees Fahrenheit) for more than one hour.”  
  
Planned oncology therapy is defined as completion of one year of therapy for advanced breast 
cancer in the absence of disease progression or cessation of study drug due to progressive 
disease or non -hematological toxicity.  
  
Secondary Endpoints  
  
1. Number of patients who required dose delays in palbociclib attributed to neutropenia.  
2. Number of patients who required dose reductions in palbociclib therapy attributed to 
neutropenia  
3. Rate of grade 3/4 neutropenia  
16 
 4. Clinical Benefit Rate (CBR), for those with evaluable disease, defined as the percentage of 
patients who achieved complete response, partial response and stable disease at 24 weeks  
5. To evaluate correlations between metabolite and exosomal signature w ith disease response  
6. To evaluate correlations between baseline ANC prior to cancer diagnosis and the Duffy Null 
polymorphism (SNP rs2814778 at chromosome 1q23.2) with hematological safety   
 3. STUDY DESIGN   
  
Figure 1. Study design  
  
 
 
  
  
This is a  phase II, single arm, multicenter clinical trial.  
  
Eligible patients will be self -identified Black, African or African American women with HR 
positive and HER2 negative advanced breast cancer. Patients will have histologically or 
cytologically proven di agnosis of adenocarcinoma of the breast (locoregionally recurrent or 
metastatic disease) and will be candidates to receive letrozole or fulvestrant for their advanced 
disease.  Use of anastrozole or exemestane permitted in the event of letrozole intolerance .  
 
Patients will be enrolled and will continue to receive treatment with palbociclib until disease 
progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, 
or completing [ADDRESS_458349]. If a patient comes off study because 
she completed 12 months of palbociclib/letrozole or fulvestrant on study she can continue 
commercial drugs at the treating physician’s discretion .  Use of anastrozole or exemestane 
permitted in the event of letrozole intol erance.  
  
  
Patients will undergo adverse events (AE) monitoring as per local practice. Adverse events will 

17 
 be characterized by [CONTACT_24975], frequency, severity (as graded by [CONTACT_4652] v.4.03), and 
seriousness. All grades, all causality AEs and all serious adver se events (SAEs) will be 
recorded in the case report forms (CRF). All deaths occurring up to [ADDRESS_458350] evaluable disease. The date of t umor progression will be 
recorded.  
   
3.1 Duration of therapy  
  
Treatment will continue until participation and study therapy is no longer in the patient’s best 
interest. Reasons for withdrawing a patient include, but are not limited to:  
- Disease progr ession  
- The occurrence of an adverse event or a concurrent illness. Patients removed from study for 
unacceptable treatment related adverse event(s) will be followed until resolution or stabilization 
of all treatment related adverse events to Grade 2 or lower.   
- A patient’s request to end participation  
- A patient’s non -compliance or simply significant uncertainty on the part of the Investigator that 
continued participation is prudent.  
 
  
Patients will be followed on study for a maximum of 12 months. If there are no reasons for 
withdrawing a patient at 12 months, patient can continue off study on the same therapy at the 
physician’s discretion.   
  
4. PATIENT SELECTION   
  
4.1. Inclusion Criteria   
  
Patient eligibility should be reviewed and documented by [CONTACT_4653]’s study team before patients are included in the study.  
  
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
study:  
  
1. Self-identified Black, African or African American women of ≥ [ADDRESS_458351] cancer (locoregionally recurrent or metastatic 
disease), either from the primary or a metastatic site.  
 
2. Post-menopausal status  defined by: a) age ≥60 years; b) age <[ADDRESS_458352] 12 consecutive months with no alternative pathological or 
18 
 physiological cause; c) documented bilateral oophorectomy; d) medically confirmed 
ovarian failure  OR   
a. pre/peri -menopausal, ie, not meeting the criteria for being postmenopausal who 
are also receiving ongoing treatment with LHRH agonists (goserelin or 
leuprolide); the first injection should occur at least two weeks before study start.   
 
3. ER-positive and/or P R-positive tumor (≥1% positive stained cells) based on local 
laboratory results  
 
4. HER2 -negative breast cancer based on local laboratory results (test to be used as per 
local practice). HER2 -negative tumor is determined as immunohistochemistry score 0/1+ 
or negative by [CONTACT_87368] (FISH/CISH/SISH) defined as a HER2/CEP17 ratio 
<2 or for single probe assessment a HER2 copy number <4.  
 
5. Patients must be appropriate candidates for letrozole therapy in any line of therapy or for 
fulvestrant for second line of therapy or beyond .  Use of anastrozole or exemestane 
permitted in the even t of letrozole intolerance.   
 
6. Must have received no more than [ADDRESS_458353] cancer.  
 
7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 -2 (Appendi x 
1)  
 
8. Adequate bone marrow function:  
a. Absolute Neutrophil Count (ANC) ≥ 1,000/mm 3 (1.0 x 10 9 /L);  
b. Platelets ≥100,000/mm 3 (100 x 10 9 /L);  
c. Hemoglobin ≥9 g/dL (90 g/L).  
 
9. Adequate liver function  
 
- AST and/or ALT ≤[ADDRESS_458354] (≤5.[ADDRESS_458355] if liver metastases p resent);  
- Alkaline phosphatase ≤2.[ADDRESS_458356] (≤5.[ADDRESS_458357] if bone or liver metastases present);  
- Total serum bilirubin ≤1.[ADDRESS_458358] (≤3.[ADDRESS_458359] if Gilbert’s disease).  
 
10. Adequate renal function  
- Serum creatinine ≤1.[ADDRESS_458360] or estimated creatinine clearance ≥60 mL/min.  
 
11. Resolution of all acute toxic effects of prior therapy, including radiotherapy to grade ≤1 
(except toxicities not considered a safety risk for the patient) and recovery from surgical 
procedures.  
 
12. Evidence of a personally signed and dated informed consent document indicating that 
the patient (or a legally acceptable representative) has been informed of all pertinent 
aspects of the study.  
 
13. Patients who are willing and able to comply with scheduled visits, treatment plan, 
laboratory tests, and other study pr ocedures.  
19 
   
4.2. Exclusion Criteria   
  
Patients presenting with any of the following will not be included in the study:  
  
1. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4  
 
2. Known hypersensitivity to letrozole , anastrozole,  exemestane, or fulvestrant, or any of its 
excipi[INVESTIGATOR_840], or to any palbociclib excipi[INVESTIGATOR_840].  If hypersensitivity to letrozole, anastrozole, 
exemestane, or fulvestrant, patients will be allowed to go on study as long as they don’t 
have hypersensitivity to the e ndocrine therapy they will receive.   
 
3. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically 
stable, as per Investigator’s judgment, brain metastases are permitted.  
 
4. Previous CDK4/[ADDRESS_458361] the study 
principal investigator (PI) or designee and request stud y enrollment. A patient identification 
number will be assigned, which must be used on all CRF pages and on all documentation and 
correspondence referencing that patient.  
  
5.2. Compliance   
  
Patients will be required to return all bottles of palbociclib a t the beginning of each clinical visit 
for drug accountability.  
 
Drug accountability will be performed at every clinical visit prior to dispensing drug supply for the 
next cycle(s). The number of remaining capsules will be documented and recorded to asses s 
compliance.  
  
5.3. Drug Supplies   
20 
   
The investigational drug used in the course of this trial is palbociclib (IBRANCE®).  
  
5.3.1. Dosage Form(s) and Packaging   
  
[IP_ADDRESS]. Palbociclib   
  
Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of 
palbociclib free base. The oral drug formulation will be supplied in High Density Polyethylene 
(HDPE) bottles containing 75 mg, 100 mg, or 125 mg capsules.    
  
[IP_ADDRESS]. Letrozole   
  
Commercially available letrozole will be used. Locally obtained commercial supplies of letrozole 
will be used in accordance with local regulations.  
  
[IP_ADDRESS]. Fulvestrant  
  
Commercially available fulvestrant will be used. Locally obtained commercial supplies of 
fulvestrant will be used in accordance with local regulations.  
 
[IP_ADDRESS] Anastrozole  
 
Commerically available anastrozole will be used. Locally obtained commercial supplies of 
anastrozole will be used in accordance with local regulations.  
 
[IP_ADDRESS] Exemestane  
 
Commercially available exemestane will be used. Locally obtained commercial supplies of 
exemestane will be used in accordance with local regulations.  
  
 5.3.2. Preparation and Dispensing - Palbociclib   
  
The patient number  should be recorded on the bottle label in the spaces provided by [CONTACT_366709].  Site personnel must ensure that patients clearly 
understand the directions for self -medication.  
  
Patients should be given a sufficient  supply to last until their next clinical vis it. Bottles contain 21 
capsules.  
  
Unused drug and/or empty bottles should be returned to the site at the next clinical visit. Unused 
returned medication MUST NOT be re -dispensed to patients.  
  
Palbociclib is a n agent that must be handled and administered with care.  Patients should be 
instructed to keep their medication in the bottles provided and not transfer it to any other 
container. Due to possible unknown hazards associated with topi[INVESTIGATOR_196319], capsules must not be opened and/or emptied into any vehicle 
for oral ingestion; capsules must be swallowed intact.  
[ADDRESS_458362] should be made of the patient to return all previously 
dispensed medication to the clinic and new capsules will be dispensed.  
  
  
5.3.3. Administration   
  
[IP_ADDRESS]. Palbociclib   
  
Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days 
off treatment for each 28 -day cycle (Schedule 3/1). For patients enrolled with baseline ANC 
between 1000 and 1499/uL, initial dose of palbociclib will be 100mg once daily for 21days 
followed by  [ADDRESS_458363] 
cycles, dose will be increased to 125 mg/day on the third cycle and then follow general dose 
modifications.    
  
General rules for palbociclib administration:  
- Palbociclib sh ould be taken with food.  
- Palbociclib capsules should be swallowed whole (do NOT chew, crush or open them prior to   
swallowing).  
- No capsule should be ingested if it is broken, cracked, or otherwise not intact  
- Patients should be encouraged to take their dose at approximately the same time each day.  
- Patients who miss a day’s dose entirely must be instructed NOT to “make it up” the next 
day.  
- Patients who vomit any time after taking a dose must be instructed NOT to “make it up,” and 
to resume treatment the  next day as prescribed.  
- Patients who inadvertently take [ADDRESS_458364] be instructed to skip the next 
day’s dose. Also refer to the Medication Errors (Section 8.3.1) for further details on 
medication errors and overdose.  
 
 [IP_ADDRESS]. Letro zole  
  
Letrozole will be administered orally at 2.[ADDRESS_458365] labeling and in compliance with its local prescribing information.   
  
[IP_ADDRESS]. Fulvestrant   
  
Fulvestrant will be administered as intramuscular injections at the initial dose of [ADDRESS_458366] 
labeling and in compliance with its local prescribing information.   
 
[IP_ADDRESS]. Anastrozole  
 
Anastrozole  will be administered orally at 1mg once daily as continuous daily dosing schedule 
according to product labeling and in compliance with its local prescribing information.  
22 
  
[IP_ADDRESS]. Exemestane  
 
Exemestance will be administered orally at 25mg once daily as continuous daily dosing 
schedule according to product labeling and in compliance with its local prescribing information.  
  
5.3.4. Recommended Dose Modification   
  
In the event of significant treatment -related toxicity, administration of palbociclib may nee d to be 
adjusted as described in the following sections.  As letrozole , anastrozole, exemestane, and 
fulvestrant doses cannot be reduced, letrozole , anastrozole, exemestane, or fulvestrant 
treatment may be interrupted in the case of toxicity as described b elow.  
  
Depending on the nature of the toxicity observed, treatment interruption may be required for one 
or both study drugs in the combination. In the event treatment interruption is deemed necessary 
for just one of the study drugs in the combination, tr eatment with the other drug may continue as 
planned if deemed clinically appropriate.  
  
In case of palbociclib dose delays, administration of letrozole , anastrozole, exemestane, or 
fulvestrant may continue according to the pre -planned schedule.  
  
In case  of palbociclib permanent discontinuation, the patient will undergo End of Study visits as 
described in Schedule of Activities (Table 5). Continuation of letrozole , anastrozole, 
exemestane, or  fulvestrant would be off study per treating physician discretio n.  
  
 [IP_ADDRESS]. Dosing Interruptions/Delays – Recommendations for Palbociclib   
  
Patients experiencing the following adverse events may have their treatment with palbociclib 
interrupted/delayed until criteria for retreatment are met (Section [IP_ADDRESS]).  
  
Patients should not hold or discontinue palbociclib for non -hematological side effects potentially 
or likely related to concomitant letrozole , anastrozole, exemestane, or fulvestrant therapy (eg, 
Grade 3 or long lasting Grade 2 joint pain) as per the invest igator’s judgment.  
  
Depending on when the AE resolves, a treatment interruption may lead to the patient missing all 
subsequent planned doses within that same cycle or even to delay in the initiation of the 
subsequent cycle.  
  
Doses omitted for toxicity are not replaced within the same cycle.  
  
Doses should be held until toxicity resolution as per Retreatment Criteria (Section [IP_ADDRESS]).  
  
The need for a dose reduction at the time of treatment resumption should be based on the 
criteria defined in the Dose Reductions (Section [IP_ADDRESS]).  
  
In the case of Grade 3 neutropenia, consider repeating complete blood count (CBC) monitoring 
within one week in accordance with best local practice and report in the CRF in order to 
23 
 document the level of neutropenia and the time to recovery of neutrophils to ≥1,000 cells/mm 3. 
Retreatment criteria are based on time to recovery of neutrophil count. For patient s who develop 
Grade 3 or 4 neutropenia, refer to the dose modification tables. The clinical actions taken as a 
result of Grade 3 neutropenia, including the use of G -CSF, if any, will be recorded.  
  
If a dose reduction is applied in the same cycle, the pat ient will need to return to the clinic to 
receive new drug supply.  
  
 
 
[IP_ADDRESS]. Retreatment Criteria - Palbociclib   
  
Retreatment with palbociclib following treatment interruption for treatment related toxicity may 
not occur until all of the following par ameters have been met.  
- Platelet count ≥ 50,000/mm 3  
- ANC ≥1000/mm 3 and no fever  
- Grade ≥3 non -hematologic AEs (including nausea, vomiting, diarrhea, and hypertension 
only if persisting despi[INVESTIGATOR_3062]) have recovered to grade≤1 or baseli ne 
or, at the investigator discretion, grade≤[ADDRESS_458367] not been met after > 3 weeks of dose interruption, the 
patient should permanently discontinu e palbociclib treatment. However, if a patient is deemed to 
be suitable for a lower dose of palbociclib, treatment may be resumed at a lower dose at the 
investigator’s discretion (see below for suggested dose adjustments).  
   
[IP_ADDRESS]. Dose Reductions - Palbociclib   
Following dose interruption or cycle delay the palbociclib, dose may need to be reduced when 
treatment is resumed.  Available dose levels in case of palbociclib dose reduction are reported 
in Table 2.  
 
Table 2. Available dose levels  
Recommended Dose Modification for Adverse Reactions Dose Level   Dose   
Recommended starting dose   125 mg/day   
First dose reduction   100 mg/day   
Second dose reduction   75 mg/day*   
 
*If further dose reduction below 75 mg/day is required, discontinue the treatment.  
  
Once a dose has been reduced, all subsequent cycles should be administered at that 
dose level, unless further dose reduction is required.  Dose re -escalation is not allow ed.  
24 
   
No specific dose adjustments are recommended for grade 1/2 treatment related toxicity. 
However, investigators should always manage their patients according to their medical 
judgment based on the particular clinical circumstances.  
  
All dose modific ations/adjustments must be clearly documented in the CRF along with 
reasons for dose modification/adjustment.  
Palbociclib recommended dose modifications for treatment related toxicities requiring 
treatment interruption/delay or persisting despi[INVESTIGATOR_366684] 3 and 4.  
 
Table 3. Dose modification and management for hematologic toxicities  
CTCAE grade  Dose Modifications  
Grade 1 or 2   No dose adjustment is required.   
Grade 3 neutropenia (ANC<1000/mm 3),  
thrombocytopenia (PLC < 50,000/mm 3) or 
anemia (Hgb < 8g/dL)  
  No dose adjustment is required. Consider 
repeating CBC monitoring one week later. 
Withhold initiation of next cycle until recovery 
to Grade ≤2.   
Grade 3 neutropenia (<1000 to 500/mm 3) + 
fever ≥38.5ºC and/or infection   Withhold palbociclib and initiation of next cycle 
until recovery to Grade ≤2 (≥1000/mm 3). 
Resume at next lower dose.   
Grade 4 neutropenia (ANC<500/mm 3), 
thrombocytopenia (PLC < 25,000/mm 3) or 
anemia (life threatening consequences)   Withhold palbociclib and initiation of next cycle 
until recovery to Grade ≤2. Resume at next 
lower dose.   
  
Table 4. Dose Modification and Management – Non-Hematologic Toxicities  
CTCAE Grade   Dose Modifications   
Grade 1 or 2   No dose adjustment is required.   
Grade ≥3 non -hematologic toxicity (if persisting 
despi[INVESTIGATOR_98767])   Withhold until symptoms resolve to:   
• Grade ≤1;   
• Grade ≤2 (if not considered a safety 
risk for the patient)   
Resume at the next lower dose.   
 
 5.4. Drug Storage   
  
Palbociclib, letrozole , anastrozole, exemestane, and fulvestrant should be stored in 
original containers and in accordance with the FDA approved drug label.  
  
The investigator, or an approved representative, eg, pharmacist, will ensure that all 
investigational products, including any comparative agents and/or marketed products 
are stored in a secured area with controlled access under recommended storage 
[ADDRESS_458368] patients on the storage requirements for take h ome medications 
including how to report temperature excursions.  
  
5.5. Drug Accountability   
  
The investigator’s site must maintain adequate records documenting the receipt, use, 
loss, or other disposition of palbociclib drug supply. Patients will be requ ired to return all 
bottles of palbociclib at the beginning of each clinical visit for drug accountability (see 
also Section 5.2 Compliance).  
  
The sponsor or designee will provide guidance on the destruction of unused 
investigational product (eg, at the s ite).  
  
The site will be responsible for drug destruction. The investigators must ensure that the 
drug is destroyed in compliance with applicable environmental regulations, and 
according to their approved institutional practices. All destruction must be a dequately 
documented.  
  
5.6. Concomitant Medication(s)   
  
Patients must be instructed not to take any additional medications (over -the-counter or 
other products) during the study without prior consultation with the investigator.  
  
All concomitant medicat ions required to clinically manage patients while they are 
receiving palbociclib therapy are permitted unless specified below in Sections 5.6.1 and 
5.6.2. Documentation of these medications will not be collected on the CRF but will 
need to be available fro m the patient’s medical record upon request by [CONTACT_1034].  
  
An exception will be the use of growth factors including granulocyte colony stimulating 
factor (GCSF). Growth factors should not be used for upfront prophylaxis, but may be 
used to treat neutro penia associated with clinically significant complications, and should 
follow established ASCO guidelines. Use outside this indication should be discussed 
26 
 with the study PI. Dose reduction is the preferred initial method to address neutropenia 
rather than GCSF. GCSF use will be documented in the CRF as well as other agents 
used to treat/manage AEs while on therapy.  
  
Immunizations (inactivated vaccines, including inactivated influenza vaccine) prior to 
initiation of therapy will be administered as clinical ly indicated and documented in CRF.   
  
Proton pump inhibitors (PPI): In a drug interaction trial in healthy subjects, coadministration of a  
single 125 mg dose of palbociclib with multiple doses of the PPI [INVESTIGATOR_366685] 41%, but had limited impact on AUC inferior (13% 
decrease), when compared to a single dose of palbociclib administered alone. Gi ven the 
reduced effect on gastric pH of H2 -receptor antagonists and local antacids compared to PPIs, 
the effect of these classes of acid -reducing agents on palbociclib exposure under fed conditions 
is expected to be minimal. Under fed conditions there is n o clinically relevant effect of PPIs, H2 -
receptor antagonists, or local antacids on palbociclib exposure. In another healthy subject study, 
coadministration of a single dose of palbociclib with multiple doses of the PPI [INVESTIGATOR_366686] 62% and 80%, respectively, 
when compared to a single dose of palbociclib administered alone.   
  
Surgery is allowed during protocol therapy, however it is suggested to avoid nadir of counts at 
time of surgery. Pati ents pursuing surgery must hold palbociclib therapy [ADDRESS_458369] occurred. Patients should continue endocrine 
therapy if  palbociclib is held for surgery.  
  
  
5.6.1. Prohibited Medications   
  
Anticancer agents: No additional investigational or commercial anticancer agents such as 
chemotherapy, immunotherapy, targeted therapy, biological response modifiers, or endocrine 
therapy other than letrozole , anastrozole, exemestane, or  fulvestrant will be permitted during the 
study.  
  
Strong CYP3A inhibitors/inducers: palbociclib is metabolized to multiple metabolites in a 
qualitatively similar manner in rat, dog and human liver micr osomes.  In vitro, palbociclib is 
primarily metabolized by [CONTACT_097]3A4 enzymes.  Co -administration with drugs that are strong 
CYP3A inhibitors and inducers may change the plasma concentrations of palbociclib in humans.  
  
The concurrent use of strong CYP3A inhi bitors , including amprenavir, atazanavir, boceprevir, 
clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, 
itraconazole, ketoconazole, lopi[INVESTIGATOR_054], mibefradil, miconazole, nefazodone, nelfinavir, 
posaconazole, ritonavir , saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and 
grapefruit, grapefruit juice or any product containing grapefruit, are not allowed in the study.  
  
The concurrent use of strong CYP3A inducers , including carbamazepi[INVESTIGATOR_050], felbamate, 
nevir api[INVESTIGATOR_050], phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John’s 
wort, are not allowed in the study.  
27 
   
5.6.2. Medications Not Recommended   
 
Alternative therapi[INVESTIGATOR_366687] s:  
  
CYP3A Substrates: caution must be exercised in patients receiving palbociclib in combination 
with drugs that are predominantly metabolized by [CONTACT_097]3A.  In particular, co -administration of  
 
palbociclib with CYP3A4 substrates with narrow therapeutic ind ex including, but not limited to 
alfentanil, aripi[INVESTIGATOR_4253], cyclosporine, ergotamine, fentanyl, halofantrine, pi[INVESTIGATOR_3924], quinidine, 
sirolimus, tacrolimus, triazolam are not recommended during the treatment with palbociclib.  
  
The use of herbal medicines is not recommended.  
  
6. STUDY PROCEDURES  
 
6.1. Schedule of events   
Study procedure/ 
assessment  Screening  Treatment:  one cycle =28 days  End of 
Treatmentc End of 
Studyc Cycles 1 and 2  Cycles ≥ 3  
Study day  Within 28 days prior 
to study entry  Day 1  Day 14    
Time Window  +/- 2 days  +/- 2  days  +/- 2 days  +/- 7 days  +/- 7 
days  
Procedures at screeninga 
Informed Consentd X      
Eligibility criteria 
checkliste X      
Registrationf X      
Medical Historyg X      
CBC with diff prior 
to cancer diagnosis  
(if available)s  
X      
Procedures at screening and on study  
Physical 
examination/ 
Clinical Visitsb  
X  
Per routine clinical practice   
Comorbidities 
(including DM and 
CVD)h X  
Per routine clinical practice   
ECOG PSi X Per routine clinical practice  X  
BMI X Per routine clinical practice  X  
Concomitant Meds 
Review  X X  X X  
Adverse Eventsj X X X X X X 
Medication Diaryk  X  X X  
Treatments  
Palbociclibl  Orally once daily from D1 to D21 of 
each cycle (schedule 3/1)    
Letrozolem 
 
or  Orally once daily (schedule continuous 
dosing)  
Or   
28 
  
Fulvestrantt 500mg intramuscular injection on days 
1, 15, and 29, and 500mg once every 
28 days thereafterc  
Laboratory tests/ Imaging/ Correlative Blood Studies  
Tumor assessmentn X Per routine clinical practice   
Hematology (CBC 
with diff)o X X X X X X 
Chemistryp X Per routine clinical practice   
Pregnancy testq X      
Research labsr  X X X X X 
 
Footnotes to the schedule of activities:  
aScreening: All assessments should be performed within 28 days prior to study entry.  
bClinical Visits: clinical visits will be conducted as per local practice and as clinically indicated. Physical 
Examination includes general clinical examination of major body systems .   
cEnd of Study: The End of Treatment visit will be conducted when palbociclib is permanently 
discontinued for any reason. The indicated assessments are to be obtained if not completed in the last 
week of therapy. The End of Study visit will occur [ADDRESS_458370] resolved or are determined to be “chronic” or “stable”.  
dInformed Consent : Must be obtained prior to undergoing any study specific procedures.  
eEligibility Criteria Evaluation: Patients must meet all of the eligibility criteria reported in the pr otocol 
and checklist must be filled.  
fRegistration: Patient identification number will be attributed to each patient.  
gMedical History: Medical history  includes history of disease process other than oncology (active or 
resolved). It should also include O ncological history with date of primary diagnosis, information on prior 
anti-tumor treatments and radiotherapy, and oncologic surgeries.  
hComorbidities  including diabetes mellitus (DM) and cardiovascular disease (CVD) should be 
documented as screening and  as clinically indicated. This should be part of the clinical visits.  
iECOG Performance Status : To be performed at Screening, as per routine clinical practice during the 
treatment, and at the end of treatment. ECOG performance scale is available in Protoc ol Appendix 1.  
jAdverse Events : Patients must be followed for Adverse Events (AEs) from the time they signed the 
informed consent until [ADDRESS_458371] resolved, whichever is  later. AEs (serious and non serious) should be recorded on the 
CRF from the time the patient has taken at least one dose of study treatment through last patient visit. 
AEs should be documented and recorded at each clinical visit using NCI CTC -AE version [ADDRESS_458372]. SAEs experienced by a patient after the active reporting period has ended should 
be reported to the Sponsor if the investigator becomes aware of them; at a minim um, all SAEs that the 
investigator believes have at least a reasonable possibility of being related to study drug are to be 
reported to the Sponsor.  
kPatient Medication Diary: patient will receive a new medication diary on day 1 of each cycle of and will 
return it filled and signed at the end of each cycle   
lPalbociclib Administration: Palbociclib will be administered orally once daily at the starting dose of 125 
mg, on Day 1 to Day 21 followed by 7 days off treatment (Schedule 3/1). The patient will recei ve drug 
supply at the clinical site that will be sufficient for 1 -3 months of treatment depending on the decision of 
the treating physician.  
mLetrozole , Anastrozole, and Exemestane  Administration: Letrozole will be administered orally once 
29 
 daily at the do se of 2.5 mg (continuous daily dosing schedule).   Anastrozole will be administered orally 
once daily at the dose of 1mg (continuous daily dosing schedule).  Exemestane will be administered 
orally once daily at the dose of 25mg.  Locally obtained sup plies o f letrozole , anastrozole, and 
exemestane will be used.  
nTumor Assessments: Tumor assessments are to be performed at Screening and as per local practice 
and according to the patient’s clinical status thereafter. Tumor assessment evaluation will be conducted  
as per local guidelines. Only investigators’ assessments will be recorded in the CRF.  
oHematology: To include complete blood count (CBC) with differential. To be performed to check 
patient’s eligibility at Screening, every 2 weeks (Days 1 and 14) of the first [ADDRESS_458373] local pra ctice and report in the CRF in order to document the ANC value at the time of severe 
neutropenia as well as the time to recovery of neutrophils to ≥1,000 cells/mm 3. Retreatment criteria are 
based on time to recovery of neutrophil count. For patients who de velop Grade 3 or 4 neutropenia, refer 
to the dose modification tables. If granulocyte -colony stimulating factors (G -CSF) and/or antibiotics are 
administered, their use  will be documented on the CRF.  For patients who experience a maximum of 
Grade [ADDRESS_458374] 6 cycles, complete blood counts for subsequent cycles may be 
performed every 3 months only, prior to the beginning of a cycle and as clinically indicated.   
pBlood Chemistry: To be performed to check patient’s eligibility at Screening, and as per routine clinical 
practice thereafter. Only laboratory data at Screening will be recorded on the CRF.  
qPregnancy Test (serum or urine): Required for women of childbearing potential  
rResearch labs: refer to Study Procedures Manual for collection, labeling, processing and shippi[INVESTIGATOR_3930].  
sCBC with diff prior to cancer diagnosis: this information will be collected if available    
tFulvestrant administration:  will be administered as  intramuscular injections at the initial dose of [ADDRESS_458375], or they may be 
withdrawn at any time at the discretion of the investigator or Sponsor for safety or behavioral 
reasons, or the inability of the patient to comply with the protocol required schedule of study 
visits or procedures at a given study site.  
  
Reasons why patients may discontinue or be withdrawn from the protocol may be due to the 
following:  
- Adverse events  
- Intercurrent illness  
- Disease progression  
- Patient is non -compliant  
- Patient is lost to follow -up  
- Withdrawal of consent  
  
If a patient does not return for a scheduled visit, every effort should be made to contact [CONTACT_4677]. In any circumstance, every effort should be made to document patient outcome, if 
possible. The  investigator should inquire about the reason for withdrawal, request the patient to  
return all unused investigational product, request the patient to return for a final visit, if 
applicable, and follow up with the patient regarding any unresolved AEs.  
[ADDRESS_458376] of monitoring of all adverse events (AEs), including serious 
adverse events (SAEs) at every clinical visit and monitoring of hematology to be performed to 
check patient’s eligibil ity at Screening, every 2 weeks (Days 1 and 14) of the first [ADDRESS_458377] local practice and report in the CRF in order 
to document the ANC value at the time of severe neutropenia as well as the time to recovery of 
neutrophils to ≥1,000 cells/mm 3.  Retreatment criteria are based on time to recovery of 
neutrophil count. For patients who develop Grade [ADDRESS_458378] of care and in accordance with each 
site’s institutional guidelines will be assessed to monitor for adverse events related to the 
underlying disease, treatment with palbociclib or treatment with letrozole , anastrozole, 
exemestane, or fulvestrant or supportive therapi[INVESTIGATOR_014] (see Section 8 for Adverse Event Reporting).  
  
Information  generated from these assessments may also be used to determine if an adverse 
event occurred as defined in Section 8.  
  
 7.1.1. Physical Examination   
  
A full physical examination of all major body systems will be required at Screening. Symptom 
directed p hysical examinations will be performed as per routine clinical practice during the 
study.  Only physical examination at Screening will be recorded on the CRF. Physical 
examinations performed during treatment will need to be available from the patient’s med ical 
record upon request by [CONTACT_1034].  
  
The Eastern Cooperative Oncology Group (ECOG) performance status (PS) scale will be 
required at Screening, as per routine clinical practice during the study, and at the end of 
treatment. Data collected at Screeni ng and at the end of treatment will be recorded on the CRF.  
Other ECOG PS assessments during study will need to be available from the patient’s medical 
record upon request by [CONTACT_1034].  ECOG PS scale is available in Protocol Appendix 1.  
   
7.1.2. Labo ratory Safety Assessments   
  
Blood tests will include the following:  
 
1. Hematology panel: complete blood count with differential  
2. Blood chemistry panel: ALT, ASL, alkaline phosphatase, total bilirubin, serum creatinine  
 
Blood tests will be drawn at the time points described in Table 5 (Schedule of Activities) and 
analyzed at local laboratories.  
  
31 
 Hematology panel (includes complete blood count with differential) will be performed to verify 
patient’s eligibility at Screen ing, every 2 weeks (Days 1 and 14) of the first [ADDRESS_458379] local practice and report in the CRF in order to document the 
level of neutropenia and the time to recovery of neutrophils to ≥1,000 cells/mm 3. Retreatment 
criteria are based on time to recovery of neutrophil count. For patients who develop Grade 3 or 
4 neutropenia, refer to the dose modification tables. The clinical actions taken as a result of 
Grade 3 neutropenia, including the use of G -CSF, if any, should be re corded.  
  
Blood Chemistry will be performed to verify patient’s eligibility at Screening, and as per routine 
clinical practice thereafter. Only laboratory data at Screening will be recorded on the CRF.  
During the study blood chemistry data will not be collected on the CRF but will need to be 
available from the patient’s medical record upon request by [CONTACT_1034]. In the case a 
laboratory abnormality meets the definition of AE, as determined by [CONTACT_366710] 8, this  must be captured on an AE CRF page.  
  
7.2. Tumor Assessments   
  
Tumor assessments are to be performed at Screening and as per routine clinical practice and 
according to the patient’s clinical status thereafter (see also Schedule of Activities, Table 5). 
Tumor assessment evaluation will be conducted as per local practice at each institution.   
  
Only investigators’ assessments will be recorded in the CRF.  
  
 8. ADVERSE EVENT REPORTING   
  
8.1. Adverse Events   
  
All observed or volunteered AEs regardless of  treatment group or suspected causal relationship 
to the investigational product(s) will be reported as described in the following sections.  
  
For all AEs, the investigator must pursue and obtain information adequate both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as an SAE 
requiring immediate notification to [COMPANY_007] or its designated represen tative.  For all AEs, sufficient 
information should be obtained by [CONTACT_4683]. The 
investigator is required to assess causality. Follow -up by [CONTACT_366711] a level acceptable to the 
investigator, and [COMPANY_007] concurs with that assessment.  
  
As part of ongoing safety reviews conducted by [CONTACT_1034], any non -serious adverse event 
that is determined by [CONTACT_366712]. To 
assist in the determination of case seriousness further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical study.  
32 
   
 8.2. Reporting Period   
  
For SAEs, the active reporting period to [COMPANY_007] or its designated representative begins from the 
time that the patient provides informed consent, which is obtained prior to the patient’s 
participation in the study, ie, prior to undergoing any study -relate d procedure and/or receiving 
investigational product, through and including [ADDRESS_458380]. Serious adverse events occurring to a patient after the active 
reporting period has ended should be r eported to the Sponsor if the investigator becomes aware 
of them; at a minimum, all serious adverse events that the investigator believes have at least a 
reasonable possibility of being related to study drug are to be reported to the Sponsor.  
  
AEs (serio us and non -serious) should be recorded on the CRF from the time the patient has 
taken at least one dose of palbociclib through last patient visit.  
  
If a patient begins a new anticancer therapy, the AE reporting period for non -serious AEs ends 
at the time  the new treatment is started.  Death must be reported if it occurs during the SAE 
reporting period after the last dose of investigational product, irrespective of any intervening 
treatment.  
   
8.3. Definition of an Adverse Event   
  
An AE is any untoward medical occurrence in a clinical investigation patient administered a 
product or medical device; the event need not necessarily have a causal relationship with the 
treatment or usage.  Examples of AEs include but are not limited to:  
- Abnormal test findin gs (see section 8.4)  
- Clinically significant symptoms and signs  
- Changes in physical examination findings  
- Hypersensitivity  
- Drug abuse  
- Drug dependency  
 
 Additionally, they may include the signs and symptoms resulting from:  
- Drug overdose  
- Drug withdrawal  
- Drug misuse  
 
- Drug interactions  
- Extravasation  
- Exposure during pregnancy  
- Exposure via breast feeding  
- Medication error  
- Occupation exposure  
- Worsening of signs and symptoms of the malignancy under study should be reporte d as AEs 
in the appropriate section in the CRF  
  
Disease progression assessed by [CONTACT_366713].  
[ADDRESS_458381] ration or consumption of the wrong drug, by [CONTACT_366714], at the wrong time, or at the wrong dosage strength.  
  
Such medication errors occurring to a study participant are to be captured on the medication 
error CRF which is a specific version of the adverse event (AE) page, and on the SAE form 
when appropriate. In the event of medication dosing error, the Sponsor should be notified 
immediately.  
  
Medication errors are reportable irrespective of the presence of an associated AE/SAE, 
including:  
- Medi cation errors involving patient exposure to the investigational product  
- Potential medication errors or uses outside of what is foreseen in the protocol that do or do not 
involve the participating patient.  
 
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error should be captured on the medication error version of the 
adverse event (AE) page and, if applicable, any associated adverse event(s) are c aptured on an 
adverse event (AE) CRF page.  
   
8.4. Abnormal Test Findings   
  
The criteria for determining whether an abnormal objective test finding should be reported as an 
AE are as follows:  
- Test result is associated with accompanying symptoms; and/or  
- Test result requires additional diagnostic testing or medical/surgical intervention;  and/or  
- Test result leads to a change in study dosing (outside of protocol -stipulated dose adjustments)  
or discontinuation from the study, significant additional concomitant drug treatment, or other 
therapy; and/or  
 
- Test result is considered to be an AE by [CONTACT_366715], in the absence of any of the abov e conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error does not require 
reporting as an AE.  
   
8.5. Serious Adverse Events   
  
An SAE is any untoward medical occurrence at any dose that:  
- Results in death;  
- Is life -threatening (immediate risk of death);  
- Requires inpatient hospi[INVESTIGATOR_1081];  
- Results in persistent or significant disability/incapacity (substantial disruption of the ability to 
conduct normal life f unctions);  
- Results in congenital anomaly/birth defect  
  
34 
 Progression of the malignancy under study (including signs and symptoms of progression) 
should not be reported as an SAE unless the outcome is fatal within the safety reporting period.  
Hospi[INVESTIGATOR_366688]. If the malignancy has a fatal outcome during the study or within the safety reporting 
period, then the event leading to death must be recorded as an AE and as an SAE w ith CTC 
Grade 5 (see Section on Severity Assessment).  
  
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event. An important medical event may not be immediately life -threatening and/or result 
in death o r hospi[INVESTIGATOR_059]. However, if it is determined that the event may jeopardize the patient 
or may require intervention to prevent one of the other AE outcomes, the important medical 
event should be reported as serious. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse.  
 8.5.1. Protocol -Specified Serious Adverse Events   
  
There are no protocol -specified SAEs in this study. All SAEs will be reported by [CONTACT_366716], and will be handled as SAEs in the safety database (see 
Section on SAE Reporting Requirements).  
   
8.6. Hospi[INVESTIGATOR_366689] (even less than 24 hours) in a hospi[INVESTIGATOR_61277]. Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit  (eg, from the psychiatric wing  
to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis 
unit).  An emergency room visit does not necessarily constitute a hospi[INVESTIGATOR_059]; however, the 
event leading to the emergen cy room visit should be assessed for medical importance.  
  
Hospi[INVESTIGATOR_4592]:  
- Rehabilitation facilities  
- Hospi[INVESTIGATOR_4593]  
- Respi[INVESTIGATOR_4594] (eg caregiver relif)  
- Skilled nursing facilities  
- Nursing homes  
- Same day s urgeries  
 
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical AE is 
not in itself an SAE. Examples include:  
- Admission for treatment of a preexisting condition not associated with the development of a 
new AE or  with a worsening of the preexisting condition (eg, for work -up of persistent pre -
treatment lab abnormality);  
- Social admission (eg, patient has no place to sleep);  
- Administrative admission (eg, for yearly physical examination);  
- Protocol -specified admission during a study (eg, for a procedure required by [CONTACT_17143]);  
- Optional admission not associated with a precipi[INVESTIGATOR_4596] (eg, for elective cosmetic 
surgery);  
35 
 - Hospi[INVESTIGATOR_4597] a medical AE;  
- Pre-planne d treatments or surgical procedures. These should be noted in the baseline  
documentation for the entire protocol and/or for the individual patient;  
- Admission exclusively for the administration of blood products  
  
Diagnostic and therapeutic non -invasiv e and invasive procedures, such as surgery, should not 
be reported as AEs.  However, the medical condition for which the procedure was performed 
should be reported if it meets the definition of an AE.  For example, an acute appendicitis that 
begins during the AE reporting period should be reported as the AE, and the resulting 
appendectomy should be recorded as treatment of the AE.  
  
8.7. Severity Assessment   
Adverse events will be graded according to the National Cancer Institute Common Terminology 
Criteria (NCI CTC), (Version 4.03 Publish Date: June 14, 2010).  
Note the distinction between the severity and the seriousness of an AE.  A severe event is not 
nece ssarily an SAE. For example, a headache may be severe (interferes significantly with 
patient's usual function) but would not be classified as serious unless it met one of the criteria 
for SAEs, listed above.  
  
8.8. Causality Assessment   
 
The investigator’s assessment of causality must be provided for all AEs (serious and non - 
serious); the investigator must record the causal relationship in the CRF, as appropriate, and 
report such an assessment in accordance with the serious adverse report ing requirements if 
applicable.  An investigator’s causality assessment is the determination of whether there exists 
a reasonable possibility that the investigational product caused or contributed to an AE; 
generally the facts (evidence) or arguments to su ggest a causal relationship should be provided. 
If the investigator does not know whether or not the investigational product caused the event, 
then the event will be handled as “related to investigational product” for reporting purposes, as 
defined by [CONTACT_1034] (see Section on Reporting Requirements). If the investigator's causality 
assessment is “unknown but not related to investigational product”, this should be clearly 
documented on study records.  
In addition, if the investigator determines an SAE is associated with study procedures, the 
investigator must record this causal relationship in the source documents and CRF, as 
appropriate, and report such an assessment in accordance with the SAE reporting 
requirements, if applicable.  
  
8.9. Withdrawal Due to Adverse Events (See Also Section on Patient Withdrawal)   
Withdrawal due to AE should be distinguished from withdrawal due to other causes, according 
to the definition of AE noted earlier, and recorded on the appropriate AE CRF page.  
When a patient with draws because of an SAE, the SAE must be reported in accordance with 
the reporting requirements defined below.  
  
8.10. Eliciting Adverse Event Information   
The investigator is to report all directly observed AEs and all AEs spontaneously reported by [CONTACT_4677] . In addition, each study patient will be questioned about AEs.  
  
36 
 8.11. Reporting Requirements   
Each AE is to be assessed to determine if it meets the criteria for SAEs.  If an SAE occurs, 
expedited reporting will follow local and international regu lations, as appropriate.  
  
8.11.1 Serious Adverse Event Reporting Requirements   
Reporting of Serious Adverse Events: Within [ADDRESS_458382] awareness of the event 
(immediately if the event is fatal or life -threatening), Principal Investigator [INVESTIGATOR_366690] t to [COMPANY_007] by 
[CONTACT_255982] (“SAE,” as defined below) for which reporting is required 
under this provision (as described below). Such SAEs are to be reported for (1) Study subjects 
who are assigned or, in the case of a blinded Study,  possibly assigned to receive the [COMPANY_007] 
Product or (2) individuals otherwise exposed to the [COMPANY_007] Product as described below. Principal 
Investigator [INVESTIGATOR_345882], even if 
complete information is  not yet available.   
Reporting Forms. Principal Investigator [INVESTIGATOR_366691]: (1) a 
reporting form approved by [CONTACT_17196], (2) a CIOMS form, (3) a [COMPANY_007] -
provided  Investigator -Initiated Research Seriou s Adverse Event Form , or (4) any other form 
prospectively approved by [CONTACT_4618]. The Reportable Event Fax Cover Sheet  provided by [CONTACT_345909].  
 
a. SAE Definition. An SAE is any adverse event, without regard to causality,  that is life -
threatening (i.e., causes an immediate risk of death) or that results in any of the following 
outcomes: death; in -patient hospi[INVESTIGATOR_1081]; 
persistent or significant disability or incapacity (i.e., s ubstantial disruption of the ability to 
conduct normal life functions); or a congenital anomaly or birth defect. Any other medical 
event that, in the medical judgment of the Principal Investigator, may jeopardize the subject 
or may require medical or surgi cal intervention to prevent one of the outcomes listed above 
is also considered an SAE. A planned medical or surgical procedure is not, in itself, an 
SAE.  
 
b. Exposure during Pregnancy, Exposure during Lactation, Occupational Exposure, and Lack 
Of Effect. Even though there may not be an associated SAE, exposure to the [COMPANY_007] 
Product during pregnancy, exposure to the [COMPANY_007] Product during lactation, and 
occupatio nal exposure to the [COMPANY_007] Product are reportable, and lack of effect of the [COMPANY_007] 
Product may also be reportable. These requirements are further explained in the training 
material provided by [CONTACT_4618] (see [COMPANY_007] -Provided Training, below). As used in this 
Agreement, the term SAE will be understood to include exposure during pregnancy, 
exposure during lactation, occupational exposure, and reportable instances of lack of 
effect.  
 
c. Hy’s Law Cases. Cases of potential drug -induced liver injury as assessed by [CONTACT_366717] (“Hy’s Law Cases”) are also reportable to [COMPANY_007]. If a Study subject develops 
abnormal values in aspartate transaminase (AST) or alanine transaminase or both , 
concurrent with abnormal elevations in total bilirubin and no other known cause of liver 
injury, that event would be classified as a Hy’s Law Case. As used in this Agreement, the 
term SAE will be understood to also include Hy’s Law Cases.  
 
d. Exclusions fr om SAE Reporting Requirements. Specifically excluded from the reporting 
[ADDRESS_458383] [COMPANY_007] in investigating any SAE and 
will provide any  follow -up information reasonably requested by [CONTACT_4618].  
g. Regulatory Reporting. Reporting an SAE to [COMPANY_007] does not relieve Principal Investigator [INVESTIGATOR_366692], if such reporting is 
required.  
 
h. [COMPANY_007]-Provided Training. [COMPANY_007] will make available training material that provides 
information about the SAE reporting requirements for IIR studies. Principal Investigator [INVESTIGATOR_366693] o f SAEs.  
 
 8.11.2. Non -Serious Adverse Event Reporting Requirements   
 
All AEs will be reported on the AE page(s) of the CRF. It should be noted that the form for 
collection of SAE information is not the same as the AE CRF. Where the same data are 
collected , the forms must be completed in a consistent manner. For example, the same AE term 
should be used on both forms. AEs should be reported using concise medical terminology on 
the CRFs as well as on the form for collection of SAE information.  
  
8.11.3. Spon sor Reporting Requirements to Regulatory Authorities   
Adverse event reporting, including suspected unexpected serious adverse reactions, will be 
carried out in accordance with applicable local regulations.  
  
9. CORRELATIVE STUDIES  
 
9.1 Correlative study 1: exploratory analysis of metabolite biomarkers of endocrine 
resistance   
 
Metabolomics analysis of serum: 50 ul of serum sample from each patient will be used for 
metabolomics analysis as described by [CONTACT_366718] 30 using both ultra -performance liquid 
chromatography mass spectrometer (UPLC MS) and gas chromatography -mass spectrometry 
(GC MS) at Lombardi’s Metabolomics Shared Resources. Analysis will provide a global 
distribution of specific metabolites in patients’ serum at the beginning and end of the stud y. We 
will use XCMS package (Scripps Center for Metabolomics, La Jolla, CA) to preprocess the MS 
datasets. To avoid multiple freeze -thaws, samples will be collected and stored on site and 
38 
 transported to the laboratory in one shipment.  
  
9.2 Correlative study 2: identify exosomal signature [CONTACT_366730], we will determine potential biomarkers (RNA and proteins) in serum 
and plasma that are associated with endocrine resistance. Both of these assays will  be done at 
SBI Biosciences. As with metabolomics, clinical data such as diabetes, body mass index (BMI) 
or cardiovascular history will be helpful in stratifying our findings.     
RNA -seq:  Exosomes will be isolated from plasma and serum, followed by [CONTACT_366719]. These libraries are then sequenced using a 1x 
50bp single end Illumina HiSeq NGS runs to provide enough depth of RNA sequence 
identification. (SBI's exosome RNA -Seq service can be ordered using catal og# CSEQ400A -1.)  
Mass spectrometry analysis: Exosomes isolated using ultracentrifugation as well as using 
ExoQuick. The MS service will be used to create complete exosome peptide library 
preparations. (SBI's exosome Mass Spec service can be ordered using catalog# CSEQ810A -1.)  
 9.3 Correlative study 3: identify Duffy Null polymorphism (SNP rs2814778 at 
chromosome 1q23.2)   
 
The Duffy Null polymorphism (SNP rs2814778 at chromosome 1q23.2) is known to protect 
against Plasmodium vivax  malaria and has been recently confirmed to be predictive of WBC 
and neutrophil count in African Americans. [ADDRESS_458384] consented for it.   
   
10. DATA ANALYSI S/STATISTICAL METHODS  
 
10.1. Two stage design, Sample Size, Accrual and Study duration   
 
The study is designed to assess the rate of completion of planned oncology therapy in the 
absence of a hematological event defined as epi[INVESTIGATOR_366694]/or treatment 
discontinuation due to neutropenia. Planned oncology therapy is defined as completion of one 
year of therapy for advanced breast cancer in the absence of disease progression or cessation 
of study drug due to progressive disease or non -neutropenia toxicity.  
 
There is no data about the current proportion of African American patients who meet the 
composite primary endpoint. In the phase II PALOMA -1 study 13% of patients discontinued drug 
due to adverse events. [ADDRESS_458385] that a significant number of cases was caused by 
[CONTACT_366720] (54%) experienced grade [ADDRESS_458386] been reported in the IBRANCE® clinical program, 
but the rate of events is not reported. Therefore we estimate that if 80% or more of patients will 
be abl e to receive palbociclib for advanced breast cancer without developi[INVESTIGATOR_366695]. Therefore we defined a 
completion rate if 80% as considered of clinical relevance, where a s a completion rate of 60% is 
considered non clinically meaningful.   
 
Simon's two -stage design (Simon, 1989) will be used. The null hypothesis that the true 
39 
 completion rate is 60% will be tested against a one -sided alternative. In the first stage, 13 
patients will be accrued. If there are 8 or fewer complete the therapy in the absence of a 
hematological event (defined as epi[INVESTIGATOR_366696]/or treatment 
discontinuation due to neutropenia) in these 13 patients, the study will be stopped. Oth erwise, 
22 additional patients will be accrued for a total of 35. The null hypothesis will be rejected if 26 
or more patients complete the therapy in the absence of a hematological event in 35 patients.  
 
This design yields a type I error rate of 0.05 and power of 80% when the true completion rate is 
80%. The intention -to-treat (ITT) population of this trial will be composed of patients who are 
actually enrolled and received at least one dose of palbociclib since they are on study.  
 
We anticipate accruing [ADDRESS_458387] confidence interval of 
the completion rate based on binomial calculation will be obtained. We estimate there will be no 
more than 10% epi[INVESTIGATOR_366697].   
 
The outliers and data errors will be checked. Descriptive statistics will be used to characterize 
the demographic profile of the subjects. Frequency and percentages will be used to summarize 
categorical variables. Mean (SD) or m edian (interquartile range) based on the normalization of 
the data will be used to summarize continuous variables.  
 
The incidence of hematological events during study treatment will be calculated, as well as the 
number of patients who required dose delays in palbociclib attributed to neutropenia, the 
number of patients who required dose reductions in palbociclib therapy  attributed to 
neutropenia, the rate of grade 3/4 neutropenia.  
 
For statistical purposes and for evaluation of the primary endpoint, patients who discontinue 
treatment for progressive disease, non -hematologic toxicity or other reasons (that do not include  
febrile neutropenia or other hematological toxicities) will be considered as having completed 
planned oncologic therapy.”  
 
Study drug administration will be described in terms of total and median number of weeks 
administered, doses, and reasons for devia tion from planned therapy.  
 
An exploratory subgroup analysis will be performed to see if the primary outcome differs 
between the patients with baseline ANC equal or higher than 1500/uL and the patients with 
baseline ANC between 1000 and 1499/uL. A second exploratory subgroup analysis will be 
performed for those patients who have available ANC before cancer diagnosis: baseline ANC 
prior to cancer diagnosis (equal or higher than 1500/uL versus below 1500/uL) will be correlated 
with primary outcome.  
 
For tho se with evaluable disease, clinical benefit rate at 24 weeks will be calculated. CBR is 
40 
 defined as the percentage of patients who achieved complete response, partial response and 
stable disease at 24 weeks.   
 
We will calculate the mean (SD) of specific me tabolites at each time point and graphically 
assess these measures over time with clinical response and hematological toxicity. The mean 
change in these variables from baseline to each follow -up point will be calculated. Generalized 
linear model will be ut ilized for the correlative analysis of clinical response and hematologic 
events.   
  
10.3. Safety stoppi[INVESTIGATOR_366698]. If the rate of 
febrile neutropenia is 10% or higher in this population then this would be considered a regimen  
with intermediate risk for febrile neutropenia (10 -20%) and c onsideration of prophylactic myeloid 
growth factors along with additional clinical trials should be given.  
  
If 3 patients experience symptoms of febrile neutropenia related to the treatment, then the trial 
will be terminated. We will accept a rate of les s than 10% for events of febrile neutropenia. With 
[ADDRESS_458388] binomial 90% CI 
would be (2.38% to 20.69%). The probability of observing 3 or more febrile neutropenia events, 
for a range of t rue underlying rates, is summarized in Table 5, indicating for example, that if the 
true rate is as high as 10% then the study has a 0.69 probability of observing three or more 
febrile neutropenia events when 35 patients are treated, and if as high as 15% there is a 0.91 
probability of having observed three or more.  
 
If the rate of febrile neutropenia events is higher than 10%, the likelihood of detecting it is high.  
  
Table 6. Probability of observing at least three febrile neutropenia, for a range of tr ue underlying 
event rates, with n=[ADDRESS_458389] one dose of study 
medication.  
   
10.5. Data Safety Monitoring Committee   
 
As this study is an investigator initiated study utilizing FDA approved agents it is 
considered a moderate risk  study which requires real -time monitoring by [CONTACT_978] [INVESTIGATOR_366699] (DSMC).  
 
[ADDRESS_458390] the study reviewed by [CONTACT_366721] 6 months based on information receive d.  
 
All Severe Adverse Events (SAEs) are required to be reported to the IRB. In addition, all 
SAEs will be submitted to the DSMC at time of submission to IRB and/or Sponsor.  
Based on SAEs, the IRB retains the authority to close the study to further accru al 
pending more detailed reporting and/or modifications to further reduce risk and 
maximize the safety of participating patients.  
 
DSMC recommendations should be based not only on results for the trial being 
monitored as well as on data available to the D SMC from other studies. It is the 
responsibility of the PI [INVESTIGATOR_366700] -confidential 
results from related studies that become available. It is the responsibility of the DSMC to 
determine the extent to which this informati on is relevant to its decisions related to the 
specific trial being monitored.   
 
A written copy of the DSMC recommendations will be given to the trial PI [INVESTIGATOR_72616]. If 
the DSMC recommends a study change for patient safety or efficacy reasons the trial P I 
must act to implement the change as expeditiously as possible. In the unlikely event 
that the trial PI [INVESTIGATOR_366701], then the Lombardi Cancer Center 
Associate Director of Clinical Research must be informed of the reason for the 
disagreem ent. The trial PI, DSMC Chair, and the Lombardi Cancer Center ADCR will be 
responsible for reaching a mutually acceptable decision about the study. Confidentiality 
must be preserved during these discussions. However, in some cases, relevant data 
may be sha red with other selected trial investigators and staff to seek advice to assist in 
reaching a mutually acceptable decision.  
 
If a recommendation is made to change a trial for reasons other than patient safety or 
efficacy the DSMC will provide an adequate r ationale for its decision.  
  
11. QUALITY CONTROL AND QUALITY ASSURANCE   
 
During study conduct, [COMPANY_007] or its agent will conduct periodic monitoring visits to ensure 
42 
 that the protocol and Good Clinical Practices (GCPs) are being followed. The monitors 
may review source documents to confirm that the data recorded on CRFs is accurate. 
The investigator and institution will allow [COMPANY_007] monitors/auditors or its agents and 
appropriate regulatory authorities direct access to source documents to perform this 
verification.  
 
The study site may be subject to review by [CONTACT_1201], and/or to quality assurance audits 
performed by [CONTACT_4618], or companies working with or on behalf of [COMPANY_007], and/or to 
inspection by [CONTACT_4708]. It is important that the in vestigator(s) 
and their relevant personnel are available during the monitoring visits and possible 
audits or inspections and that sufficient time is devoted to the process.  
  
 
 
 
12. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]   
  
12.1. Case Report Forms/Electronic Da ta Record   
As used in this protocol, the term CRF should be understood to refer to an electronic 
data record. A CRF is required and should be completed for each included patient.   
The investigator has ultimate responsibility for the collection and reporti ng of all clinical, 
safety and laboratory data entered on the CRFs and any other data collection forms 
(source documents) and ensuring that they are accurate, authentic / original, 
attributable, complete, consistent, legible, timely (contemporaneous), endu ring and 
available when required. Blood chemistry laboratory data during the treatment period, 
ECGs, and concomitant medications will not be collected on the CRF; however, [COMPANY_007] 
retains the right to view source documents if needed (see Section 10 above). The CRFs 
must be signed by [CONTACT_366722]. Any corrections to entries made in the CRFs or 
source documents must be dated, initialed and explained (if necessary) and sh ould not 
obscure the original entry.  
 
In most cases, the source documents are the hospi[INVESTIGATOR_307]'s or the physician's patient chart. 
In these cases data collected on the CRFs must match the data in those charts.  
In some cases, the CRF, or part of the CRF, may also serve as source documents. In 
these cases, a document should be available at the investigator’s site as well as at 
[COMPANY_007] and clearly identify those data that will be recorded in the CRF, and for which t he 
CRF will stand as the source document.  
  
12.2. Record Retention   
To enable evaluations and/or audits from regulatory authorities or [COMPANY_007], the 
investigator agrees to keep records, including the identity of all participating patients 
(sufficient inform ation to link records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed 
43 
 informed consent documents, copi[INVESTIGATOR_4600], safety reporting forms, source 
documents, and detailed records of treatment disposition, and adequate documentation 
of relevant corre spondence (eg, letters, meeting minutes, telephone calls reports).  The 
records should be retained by [CONTACT_366723] (ICH), local regulations, or as specified in the Clinical Study Agreement 
(CSA), w hichever is longer.  
 
If the investigator becomes unable for any reason to continue to retain study records for 
the required period (eg, retirement, relocation), [COMPANY_007] should be prospectively notified. 
The study records must be transferred to a designee acceptable to [COMPANY_007], s uch as 
another investigator, another institution, or to an independent third party arranged by 
[CONTACT_4618]. Investigator records must be kept for a minimum of [ADDRESS_458391] obtain [COMPANY_007]'s written permission before disposing of any records, 
even if retention requirements have been met.  
  
13. ETHICS   
  
13.1. Institutional Review Board (IRB)   
 
It is the responsibility of the investigator  to have prospective approval of the study 
protocol, protocol amendments, informed consent documents, and other relevant 
documents, eg, recruitment advertisements, if applicable, from the IRB.  All 
correspondence with the IRB/EC should be retained in the I nvestigator File. Copi[INVESTIGATOR_366702].  
The only circumstance in which an amendment may be initiated prior to IRB approval is 
where the change is necessary to eliminate apparent immediate hazards to the patients.  
In that event, the investigator must notify the IRB and [COMPANY_007] in writing immediately after 
the implementation.  
  
13.2. Ethical Conduct of the Study   
 
This protocol will be conducted in accordance with legal and regulatory requirements, 
as well as the general pri nciples set forth in the International Ethical Guidelines for 
Biomedical Research Involving Human Patients (Council for International Organizations 
of Medical Sciences 2002), Guidelines for GCP (ICH 1996), and the Declaration of 
Helsinki (World Medical Ass ociation 2008).   
In addition, the study will be conducted in accordance with the protocol, the ICH 
guideline on GCP, and applicable local regulatory requirements and laws.  
  
13.3. Patient Information and Consent   
[ADDRESS_458392]’s actual identity. In case of data transfer, 
[COMPANY_007] will maintain high standards of confidentiality and protection of pat ient personal 
data consistent with applicable privacy laws. The informed consent/assent document 
must be in compliance with ICH GCP, local regulatory requirements, and legal 
requirements, including applicable privacy laws.  
 
The informed consent/assent doc ument(s) used during the informed consent process 
must be reviewed by [CONTACT_1034], approved by [CONTACT_112392], and available for 
inspection.  
 
The investigator must ensure that each study patient, or his/her legally acceptable 
representative, is fully informed about the nature and objectives of the study and 
possible risks associated with participation.  
 
Whenever consent is obtained from a patient's legally acceptable representative, the 
patient’s assent (affirmative agreement) must subsequently be obt ained when the 
subject has the capacity to provide assent, as determined by [CONTACT_1201]/EC.  If the 
investigator determines that a patient’s decisional capacity is so limited she cannot 
reasonably be consulted, as permitted by [CONTACT_366724], then the patient’s assent may be waived with source 
documentation of the reason assent was not obtained.  If the study patient does not 
provide her own consent, the source documents must record why the patient did not 
provide consent (eg, decisionally impaired adult), how the investigator determined that 
the person signing the consent was the subject’s legally acceptable representative, the 
consent signer’s relationship to the study subject and that the patient’s assent w as 
obtained, or waived.  If assent is obtained verbally it must be documented in the source 
documents.  
 
The investigator, or a person designated by [CONTACT_093], will obtain written informed 
consent from each patient or the patient's legally acceptabl e representative before any 
study - specific activity is performed, unless a waiver of informed consent has been 
granted by [CONTACT_2717].  The investigator will retain the original of each patient's signed 
consent/assent document  
45 
   
13.4. Reporting of Safety Issu es and Serious Breaches of the Protocol or ICH GCP   
 
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_225978], or if the investigator is aware of any new information which might 
influence the evaluatio n of the benefits and risks of the investigational product, [COMPANY_007] 
should be informed immediately.  
 
In addition, the investigator will inform [COMPANY_007] immediately of any urgent safety measures 
taken by [CONTACT_4713], 
and of any serious breaches of this protocol or of ICH GCP that the investigator 
becomes aware of. Except for an emergency situation in which proper care for the 
protection, safety, and well -being of the study patient requires alterna tive treatment, the 
study shall be conducted exactly as described in the approved protocol.    
 
a. Emergency Modifications: Investigators may implement a deviation from, or a 
change of, the protocol to eliminate an immediate hazard(s) to trial subjects withou t 
prior IRB approval. For any such emergency modification implemented, an IRB 
modification form must be completed within five (5) business days of making the 
change.    
 
b. Single Patient/Subject Exceptions: Any request to enroll a single subject who does 
not meet all the eligibility criteria of this study requires the approval of the Principal 
Investigator [INVESTIGATOR_72616].   
 
c. Other Protocol Deviations/Violations: All other planned deviations from the protocol 
must have prior approval by [CONTACT_079]  [INVESTIGATOR_72616].  
 
According to the IRB, a protocol deviation is any unplanned variance from an IRB 
approved protocol that:   
• Is generally noted or recognized after it occurs  
• Has no substantive effect on the risks to research participants  
• Has no substantive effect on the scientific integrity of the research plan or the value of the data   
collected   
• Did not result from willful or knowing misconduct on the part of the investigator(s).   
 
 An unplanned protocol variance is considered a vio lation if the variance:  
• Has harmed or increased the risk of harm to one or more research participants.  
• Has damaged the scientific integrity of the data collected for the study.  
• Results from willful or knowing misconduct on the part of the investig ator(s).  
• Demonstrates serious or continuing noncompliance with federal regulations, State laws, or   
University policies.  
 
46 
 If a deviation or violation occurs without prior approval from the Principal Investigator, please 
follow the guidelines below:  
a. Protocol Deviations: Personnel will report to any sponsor or data and safety monitoring 
committee in accordance with their policies. Minor deviations should be summarized and 
reported to the IRB at the time of continuing review. Major deviations should be 
summarized and reported to the Regulatory Affairs Coordinator who will submit to the IRB 
as soon as possible, but not more than 10 calendar days after acquiring information 
reasonably suggesting that a reportable (major) deviation has occurred.   
 
b. Protocol V iolations: Violations should be reported by [CONTACT_289912] (1) week 
of the investigator becoming aware of the event using the same IRB online mechanism 
used to report Unanticipated Problems.    
 
13.5. Amendments to the Protocol  
 
Should amendme nts to the protocol be required, the amendments will be originated and 
documented by [CONTACT_079]. It should also be noted that when an amendment to 
the protocol substantially alters the study design or the potential risk to the patient, a re vised 
consent form might be required.    
 
The written amendment, and if required the amended consent form, must be sent to the IRB for 
approval prior to implementation.    
     
14. REFERENCES  
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: [ADDRESS_458393] cancer on 
recurrence and 15 -year survival: an overview of the randomized trials. Lan cet 2005; 365: [ADDRESS_458394]. In: DeVita VT Jr, 
Hellmann S, Rosenberg SA, editors. Cancer, Principle and Practice of Oncology, 7 thEdition, 
Lippi[INVESTIGATOR_4603]; 2005; 1415 -1477.   
4. Leung, BS, Potter AH. Mode of estrogen action on cell proliferation in CAMA -1 cells. II. 
Sensitivity of G1 phase population. J. Cell. Biochem. 1987; 34:213 -225.   
5. Sutherland RL, Hall RE, Ta ylor IW. Cell proliferation kinetics of MCF -7 human mammary 
carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau -phase 
cells. Cancer Res. 1983; 43:[ADDRESS_458395] cancer in 
postmenopausal women: analysis of survival and update of efficacy from the international 
Letrozole Breast Cancer Group. Journal of Clinic al Oncology 2003; 2101 -2109.   
7. Finn RS, Dering J, Conklin D, et al. PD -0332991, a selective cyclin D kinase 4/[ADDRESS_458396] Cancer  Research 2009; 11(5):R77.   
8. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin -
dependent kinase inhibitor, administered in 3 -week cycles (schedule 2/1). Br J Cancer 
2011;104(12):1862 -8  
9. Flaherty KT, Lorusso PM, Demiche le A, et al. Phase I, dose -escalation trial of the oral cyclin -
dependent kinase 4/6 inhibitor PD 0332991 administered using a 21 -day schedule in patients 
with advanced cancer. Clin Cancer Res 2012;18(2):568 -76.  
47 
 10. DeMichele A, Clark AS, Tan KS, et al. CD K 4/6 inhibitor palbociclib (PD0332991) in Rb+ 
advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin 
Cancer Res 2015;21(5):995 -1001  
11. Finn RS, Crown JP, Lang I, et al. The cyclin -dependent kinase 4/[ADDRESS_458397] cancer (PALOMA -1/TRIO -18): a randomised phase 
2 study. Lancet Oncol 2015;16(1):25 -35   
12. A study of Palbo ciclib (PD -0332991) + letrozole vs. letrozole for first line treatment of 
postmenopausal women with ER/HER2 - advanced breast cancer (PALOMA -2). Available at: 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. Accessed on August 9, [ADDRESS_458398] Cancer. N Engl J Med 2015;373(3):209 -19  
14. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical 
Research – Amended, October, [ADDRESS_458399]: enhanicing 
minority participation in clinical trials: laying the groundwork for improving minority clinical trial 
accrual and renewing the case for enhancing minority participati on in cancer clinical trials. 
Cancer 2014;120:[ADDRESS_458400] -Holt DD, et al. Prevalence of neutropenia in the US 
population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007;146(7):486 -
92.  
17. Reich D, Nalls MA, Kao L, et al. Reduced Neutrophil count in people of African descent is 
due to a regulatory variant in the duffy antigen receptor for chemokines gene. PLoS Genet 
2009;5(1).  
18. Hsieh MM, Tisdale JF, Rodgers GP, et al. Neutrophil Count in African Americ ans: Lowering 
the Target Cutoff to Initiate or resume chemotherapy?. J Clin Oncol 2010; 28,[ADDRESS_458401] 2003;95(20):[ADDRESS_458402] cancer research. Metabolites 2015;5(1):100 -18.   
21. Nowicki S, Gottlieb E. Oncometabolites: tailoring our g enes. FEBS J. 2015;282(15):[ADDRESS_458403] Cancer. Pathobiology 2015;82(3 -4):[ADDRESS_458404] cancer. Mol 
Cancer 2014;13:239.  
24. Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using 
metabolite profiling. Cancer Res 2010;70(21):8309 -18.  
25. Lowry MC, Gallagher WM, O’Dr iscoll L. The role of exomes in Breast Cancer. Clin Chem 
[ADDRESS_458405] cancer cells and a probable mechanism is delivery of P -glycoprotein. Tumour Biol 
2014;35(11):[ZIP_CODE] -9  
29. Kelly DL, Kreyenbuhl J, Dixon L, et al. Clozapi[INVESTIGATOR_366703]. Schizophr Bull 2007; 33(5): 1221 -1224.  
30. Xiao JF, Varghese RS, Zhou B, et al. LC -MS based serum metabolomics for identification of 
hepatocellular carcinoma biomarkers in Egyptian coho rt. J Proteome Res 2012;11(12):[ADDRESS_458406] OF APPENDICES  
 
Appendix 1. Eastern Cooperative Oncology Group (ECOG) Performance Status  
Grade  ECOG Performance Status  
0  Fully active, able to carry on all pre -disease performance without restriction  
1  Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work  
2  Ambulatory and capable of all selfcare but unable to carry out any work activities.   
Up and about more than 50% of waking hours  
3  Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours  
4  Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5  Dead  
 
  
* As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, 
J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The 
Eastern Cooperative Oncology Group. Am J Clin Oncol 5:[ADDRESS_458407] Review  
NCI  National Cancer Institute  
NIH  National Institute of Health  
ORR  Overall response rate  
PFS  Progression Free Survival  
PI  [INVESTIGATOR_366704]2D  Recommended phase 2 dose  
SAE  Serious Adverse Event  
SD  Stable Disease  
SNP  Single Nucleotide Polymorphisms  
TTF  Time to treatment failure  
TTP  Time to treatment progression  
WBC  White blood count  
 
 
 
 
 
 
 
 
 
 
50 
  
 
PATIENT MEDICATION DIARY (Palbociclib + Letrozole , Anastrozole, or Exemestane )  
Study: Phase II Safety Study of Palbociclib with Letrozole or Fulvestrant in African 
American Women with Hormone Receptor Positive HER2 Negative Advanced Breast 
Cancer  
Subject #: _________________                Site: ______________  
Cycle #:_____________ ______                Current dose of palbociclib: ___________ mg  
Take one Palbociclib capsule with food on Days 1 -21.  Take one Letrozole, Anastrozole, or Exemestane tablet 
on Days 1 -28.  If you miss a day’s dose entirely, you should NOT  make it up the ne xt day.  If you inadvertently 
take 1 extra dose during a day, you should NOT  take the next day’s dose.  Unused drug and/or empty bottles 
should be RETURNED  to the site at the next study visit.  Please record your diary daily.  Always bring your 
completed p atient diary to the clinic at EACH  study visit.  
  
Date taken 
(mm/dd/yyy)     
Palbociclib  ☐ Letrozole  
☐ Anastrozole   
☐ Exemestane   Comments   
(Please use this section to write down 
explanation for any missed doses)   
Day 1       /      /  ☐ ☐   
Day 2      /      /  ☐ ☐   
Day 3       /      /  ☐ ☐   
Day 4  /      /  ☐ ☐   
Day 5   /      /  ☐ ☐   
Day 6  /      /  ☐ ☐   
Day 7   /      /  ☐ ☐   
Day 8  /      /  ☐ ☐   
Day 9   /      /  ☐ ☐   
Day 10  /      /  ☐ ☐   
Day 11   /      /  ☐ ☐   
Day 12  /      /  ☐ ☐   
Day 13   /      /  ☐ ☐   
Day 14  /      /  ☐ ☐   
Day 15   /      /  ☐ ☐   
Day 16  /      /  ☐ ☐   
Day 17   /      /  ☐ ☐   
Day 18  /      /  ☐ ☐   
Day 19   /      /  ☐ ☐   
Day 20  /      /  ☐ ☐   
Day 21   /      /  ☐ ☐   
Day 22  /      /    ☐   
Day 23   /      /   ☐   
Day 24  /      /    ☐   
Day 25   /      /    ☐   
Day 26  /      /    ☐   
Day 27  /      /    ☐   
Day 28  /      /    ☐   
51 
  
Patient signature: ____________________________________   Date: _____/_____/_____  
PATIENT MEDICATION DIARY (Palbociclib + Fulvestrant)   
Study: Phase II Safety Study of Palbociclib with Letrozole or Fulvestrant in African 
American Women with Hormone Receptor Positive HER2 Negative Advanced Breast 
Cancer  
Subject #: _________________                Site: ______________  
Cycle # :___________________                Current dose of palbociclib: ___________mg  
 
Take one Palbociclib capsule with food on Days 1 -21.  If you miss a day’s dose entirely, you 
should NOT  make it up the next day. If you inadvertently take 1 extra dose during a day, you 
should NOT take the next day’s dose. Unused drug and/or empty bottles should be 
RETURNED to the site at the next visit.  Please record your diary daily. Always bring your 
completed patient diary to the clinic at EACH study visit.  
 
  Date taken (mm/dd/yyy)     
Palbociclib    
Fulvestrant  Comments   
(Please use this 
section to write 
down explanation 
for any missed 
doses)   
Day 1       /      /  ☐ ☐   
Day 2      /      /  ☐    
Day 3       /      /  ☐    
Day 4  /      /  ☐    
Day 5   /      /  ☐    
Day 6  /      /  ☐    
Day 7   /      /  ☐    
Day 8  /      /  ☐    
Day 9   /      /  ☐    
Day 10  /      /  ☐    
Day 11   /      /  ☐    
Day 12  /      /  ☐    
Day 13   /      /  ☐    
Day 14  /      /  ☐    
Day 15   /      /  ☐ ☐   
Day 16  /      /  ☐    
Day 17   /      /  ☐     
Day 18  /      /  ☐     
Day 19   /      /  ☐     
Day 20  /      /  ☐     
Day 21   /      /  ☐     
Day 22  /      /        
Day 23   /      /        
Day 24  /      /        
Day 25   /      /        
Day 26  /      /        
Day 27   /      /        
Day 28  /      /        
52 
  
  
Patient signature: ____________________________________   Date: _____/_____/_____  